These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Development of treatment strategies to combat Ebola and Marburg viruses. Paragas J; Geisbert TW Expert Rev Anti Infect Ther; 2006 Feb; 4(1):67-76. PubMed ID: 16441210 [TBL] [Abstract][Full Text] [Related]
10. Pathology of experimental Ebola virus infection in African green monkeys. Involvement of fibroblastic reticular cells. Davis KJ; Anderson AO; Geisbert TW; Steele KE; Geisbert JB; Vogel P; Connolly BM; Huggins JW; Jahrling PB; Jaax NK Arch Pathol Lab Med; 1997 Aug; 121(8):805-19. PubMed ID: 9278608 [TBL] [Abstract][Full Text] [Related]
11. Reduced virus replication, proinflammatory cytokine production, and delayed macrophage cell death in human PBMCs infected with the newly discovered Bundibugyo ebolavirus relative to Zaire ebolavirus. Gupta M; Goldsmith CS; Metcalfe MG; Spiropoulou CF; Rollin PE Virology; 2010 Jun; 402(1):203-8. PubMed ID: 20394957 [TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with filovirus envelope glycoproteins. Barrientos LG; Lasala F; Otero JR; Sanchez A; Delgado R J Infect Dis; 2004 Apr; 189(8):1440-3. PubMed ID: 15073681 [TBL] [Abstract][Full Text] [Related]
13. Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections. Geisbert TW; Hensley LE; Geisbert JB; Jahrling PB Virology; 2002 Feb; 293(1):15-9. PubMed ID: 11853394 [TBL] [Abstract][Full Text] [Related]
14. An analysis of features of pathogenesis in two animal models of Ebola virus infection. Ryabchikova EI; Kolesnikova LV; Luchko SV J Infect Dis; 1999 Feb; 179 Suppl 1():S199-202. PubMed ID: 9988185 [TBL] [Abstract][Full Text] [Related]
15. Ebola virus defective interfering particles and persistent infection. Calain P; Monroe MC; Nichol ST Virology; 1999 Sep; 262(1):114-28. PubMed ID: 10489346 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of Lassa virus and Ebola virus infection in host cells treated with the kinase inhibitors genistein and tyrphostin. Kolokoltsov AA; Adhikary S; Garver J; Johnson L; Davey RA; Vela EM Arch Virol; 2012 Jan; 157(1):121-7. PubMed ID: 21947546 [TBL] [Abstract][Full Text] [Related]
17. Development and characterization of a stable eGFP enterovirus 71 for antiviral screening. Shang B; Deng C; Ye H; Xu W; Yuan Z; Shi PY; Zhang B Antiviral Res; 2013 Feb; 97(2):198-205. PubMed ID: 23267829 [TBL] [Abstract][Full Text] [Related]
18. Molecular determinants of Ebola virus virulence in mice. Ebihara H; Takada A; Kobasa D; Jones S; Neumann G; Theriault S; Bray M; Feldmann H; Kawaoka Y PLoS Pathog; 2006 Jul; 2(7):e73. PubMed ID: 16848640 [TBL] [Abstract][Full Text] [Related]
19. Current knowledge on lower virulence of Reston Ebola virus (in French: Connaissances actuelles sur la moindre virulence du virus Ebola Reston). Morikawa S; Saijo M; Kurane I Comp Immunol Microbiol Infect Dis; 2007 Sep; 30(5-6):391-8. PubMed ID: 17610952 [TBL] [Abstract][Full Text] [Related]
20. Pathologic findings associated with delayed death in nonhuman primates experimentally infected with Zaire Ebola virus. Larsen T; Stevens EL; Davis KJ; Geisbert JB; Daddario-DiCaprio KM; Jahrling PB; Hensley LE; Geisbert TW J Infect Dis; 2007 Nov; 196 Suppl 2():S323-8. PubMed ID: 17940967 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]